BTIG Reiterates Buy on Humacyte, Maintains $10 Price Target

Benzinga · 10/18 14:53
BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $10 price target.